MARKET

NVIV

NVIV

InVivo
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.558
-0.032
-2.01%
After Hours: 1.550 -0.008 -0.51% 19:36 04/08 EDT
OPEN
1.580
PREV CLOSE
1.590
HIGH
1.960
LOW
1.490
VOLUME
1.70M
TURNOVER
--
52 WEEK HIGH
50.70
52 WEEK LOW
1.085
MARKET CAP
921.89K
P/E (TTM)
-0.0015
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NVIV stock price target is 37.50 with a high estimate of 37.50 and a low estimate of 37.50.

EPS

NVIV News

More
  • NVAX, INSG among premarket gainers
  • Seeking Alpha - Article · 04/01 13:20
  • The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
  • Benzinga · 03/17 15:38
  • INO, MNK among premarket gainers
  • Seeking Alpha - Article · 03/12 13:16
  • InVivo Therapeutics Announces Closing of $7.0 Million Public Offering
  • Business Wire · 03/11 20:27

Industry

Advanced Medical Equipment & Technology
+3.77%
Healthcare Equipment & Supplies
+4.03%

Hot Stocks

Symbol
Price
%Change

About NVIV

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company's approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.
More

Webull offers kinds of Invivo Therapeutics Holdings Corp stock information, including NASDAQ:NVIV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVIV stock news, and many more online research tools to help you make informed decisions.